 movie S1 (.mov format). EV collection followed by miRNA extraction in urine using the nanowire-anchored microfluidic device.  data S1 (Microsoft Excel format). Logarithmic signal intensities in noncancer miRNAs with those in cancer miRNAs.
fig. S1. Schematic of the fabrication procedure for nanowires anchored into PDMS. (a-g) The
nanowires are anchored into PDMS by utilizing lithographic techniques and a PDMS curing process.
Components include Si substrate (dark cyan), OFPR8600 photoresist (pink), Cr layer (faded cyan), and 24, respectively). Pink and cyan circles show EV concentrations of 10 9 and 10 10 particles/mL, respectively. After introduction of EVs, PBS was introduced into three different devices to remove uncollected EVs. The first device had ZnO nanowires, the second had ZnO/Al2O3 core-shell nanowires, and the third had no nanowires. Then, we introduced 1% BSA solution into each device and let this stand for 15 min. After washing out each device using PBS, we introduced a mouse monoclonal anti-human CD9 (10 µg/mL, Abcam, Plc.), which is also a well-known membrane protein expressed on exosomes, into each device, and then let this stand for 15 min. Additionally, we washed out each device using PBS, and introduced a goat polyclonal anti-mouse AlexaFluor488-labeled IgG secondary antibody (5 µg/mL, Abcam, Plc.) into each device, and then let this stand for 15 min. Finally, we washed out each device using PBS and followed that by fluorescence intensity observation under a fluorescence microscope (Olympus, Co., Ltd.). We found that ZnO nanowires could collect EVs efficiently while ZnO/Al2O3 core-shell nanowires could collect EVs only slightly; these findings led us to conclude that the nanowire surface charge was the dominant factor. As EV-free miRNA, we used a 100-nM miRNA (sequence, uugcauagucacaaaagugauc). The designation "no treatment" represents the 100-nM miRNA quantity. Recovery rates of microchannels with and without nanowires were 100 and 23 %, respectively. fig. S10 . Size distribution of the urinary free-floating objects. The urinary free-floating object size distribution and concentration were measured using a nanoparticle detector (qNano, Meiwafosis
nanowires (gray) and PDMS (transparent cyan). (h)
Co., Ltd.) with a 100 nm nanopore membrane (NP100, Meiwafosis Co., Ltd.). (a) The urinary free-floating objects in the untreated urine; concentration was 1.4×10 12 mL -1 . (b) The urinary free-floating objects in the flow-through fraction of the urine being processed by the nanowire-anchored microfluidic device; concentration was 2.4×10 10 mL -1 (capturing efficiency, 99%). (c) The urinary free-floating objects in the flow-through fraction of the urine being processed by a nanowire-anchored microfluidic device without the herringbone structure (only a microchannel); concentration was 4.3×10 11 mL -1 (capturing efficiency, 61%).
movie S1. EV collection followed by miRNA extraction in urine using the nanowire-anchored microfluidic device. data S1. Logarithmic signal intensities in noncancer miRNAs with those in cancer miRNAs.
